Literature DB >> 1730494

In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins.

K Emancipator1, G Csako, R J Elin.   

Abstract

A chromogenic Limulus amebocyte lysate assay was used to measure the recovery of 1 endotoxin unit of endotoxin per ml. Purified human high-density lipoprotein, low-density lipoprotein, and apolipoprotein A1 (apo A1) at a maximum concentration of 1 g of protein per liter reduced the recovery to less than 40% of baseline in a both dose- and time-dependent manner and in the absence of other serum components. Furthermore, the lapine fever response to a dose of 1 ml of 5-ng/ml endotoxin per kg was reduced by greater than 0.5 degrees C (P less than 0.005) when the solution was preincubated in vitro with 0.5 g of apo A1 per liter. By the Limulus test, a maximum concentration of 0.01 g of apolipoprotein B (apo B) per liter (which contained deoxycholate, a known endotoxin-disaggregating agent) reduced recovery to 0% in a dose- but not time-dependent manner. In heat-inactivated (56 degrees C, 1 h) normal human serum, high-density lipoprotein cholesterol (P less than 0.005) and apo A1 (P less than 0.05) correlated inversely with endotoxin recovery, but, paradoxically, apo B correlated directly with endotoxin recovery (P less than 0.05), while low-density lipoprotein cholesterol showed no significant correlation. INTRALIPID alone had no effect on endotoxin recovery. Addition of a maximum of 10 g of INTRALIPID per liter to 0.0042 g of apo B per liter increased endotoxin recovery from approximately 30 to 80% (P less than 0.001), but addition of INTRALIPID to 0.25 g of apo A1 per liter decreased recovery from approximately 30 to 20% (P less than 0.001). We conclude that (i) lipoproteins are endotoxin inactivators; (ii) this ability of lipoproteins may be modulated by their lipid component (lipid-endotoxin interaction); (iii) apo A1 is capable of directly inactivating endotoxin (protein-endotoxin interaction).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730494      PMCID: PMC257670          DOI: 10.1128/iai.60.2.596-601.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Correlation between endotoxin-neutralizing capacity of human plasma as tested by the limulus-amebocyte-lysate-test and plasma protein levels.

Authors:  D Berger; S Schleich; M Seidelmann; H G Beger
Journal:  FEBS Lett       Date:  1990-12-17       Impact factor: 4.124

2.  Neutralization and lipoprotein binding of lipopolysaccharides in tolerant rabbit serum.

Authors:  H S Warren; C V Knights; G R Siber
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

3.  Structure and function of lipopolysaccharide binding protein.

Authors:  R R Schumann; S R Leong; G W Flaggs; P W Gray; S D Wright; J C Mathison; P S Tobias; R J Ulevitch
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

4.  Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins.

Authors:  W A Flegel; A Wölpl; D N Männel; H Northoff
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

5.  Effects of specific antibodies, hormones, and lipoproteins on bacterial lipopolysaccharides injected into the rat.

Authors:  R S Munford; J M Dietschy
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

6.  Neutralization of bacterial lipopolysaccharides by human plasma.

Authors:  H S Warren; T J Novitsky; P A Ketchum; P F Roslansky; S Kania; G R Siber
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

7.  Control of lipopolysaccharide-high-density lipoprotein interactions by an acute-phase reactant in human serum.

Authors:  P S Tobias; K P McAdam; K Soldau; R J Ulevitch
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

8.  The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide.

Authors:  B J Van Lenten; A M Fogelman; M E Haberland; P A Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

9.  Detection of endotoxin in triglyceride-rich lipoproteins in vitro.

Authors:  H W Harris; E B Eichbaum; J P Kane; J H Rapp
Journal:  J Lab Clin Med       Date:  1991-08

10.  Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides.

Authors:  R S Munford; C L Hall; J M Lipton; J M Dietschy
Journal:  J Clin Invest       Date:  1982-10       Impact factor: 14.808

View more
  47 in total

1.  Distribution and kinetics of lipoprotein-bound endotoxin.

Authors:  J H Levels; P R Abraham; A van den Ende; S J van Deventer
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Authors:  T Kawata; J R Bristol; D P Rossignol; J R Rose; S Kobayashi; H Yokohama; A Ishibashi; W J Christ; K Katayama; I Yamatsu; Y Kishi
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

3.  Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Authors:  J R Rose; M A Mullarkey; W J Christ; L D Hawkins; M Lynn; Y Kishi; K M Wasan; K Peteherych; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Apolipoprotein A-I attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony-stimulating factor-dependent mechanism.

Authors:  Cuilian Dai; Xianglan Yao; Karen J Keeran; Gayle J Zywicke; Xuan Qu; Zu-Xi Yu; Pradeep K Dagur; J Philip McCoy; Alan T Remaley; Stewart J Levine
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-15       Impact factor: 6.914

5.  Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia.

Authors:  D Pajkrt; J E Doran; F Koster; P G Lerch; B Arnet; T van der Poll; J W ten Cate; S J van Deventer
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

6.  Effect of hypertriglyceridemia on endotoxin responsiveness in humans.

Authors:  T van der Poll; C C Braxton; S M Coyle; M A Boermeester; J C Wang; P M Jansen; W J Montegut; S E Calvano; C E Hack; S F Lowry
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Apolipoprotein A-I binding to anionic vesicles and lipopolysaccharides: role for lysine residues in antimicrobial properties.

Authors:  Wendy H J Beck; Christopher P Adams; Ivan M Biglang-Awa; Arti B Patel; Heather Vincent; Eric J Haas-Stapleton; Paul M M Weers
Journal:  Biochim Biophys Acta       Date:  2013-02-26

8.  Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins.

Authors:  Sylvette Bas; Richard W James; Cem Gabay
Journal:  BMC Immunol       Date:  2010-09-16       Impact factor: 3.615

Review 9.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Chylomicrons enhance endotoxin excretion in bile.

Authors:  T E Read; H W Harris; C Grunfeld; K R Feingold; M C Calhoun; J P Kane; J H Rapp
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.